Lantheus (LNTH) Stock Price, News & Analysis

Company Overview

Lantheus Holdings, Inc. is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow. On the molecular imaging side, Lantheus markets Cardiolite® (technetium Tc-99m sestamibi) for myocardial perfusion imaging and Lexiscan® (regadenoson) for pharmacologic stress testing. In 2021, the company gained FDA approval and launched PYLARIFY® (piflufolastat F 18), a PET imaging agent for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Lantheus also maintains a robust pipeline of next-generation PET and therapeutic candidates in collaboration with academic and industry partners.

Founded in 1956, Lantheus has expanded its reach through strategic acquisitions and global partnerships, serving hospitals, imaging centers and research institutions in more than 50 countries. The company operates a network of manufacturing facilities across North America and Europe, adhering to stringent quality and regulatory standards. Lantheus’ leadership team comprises experienced executives from the pharmaceutical and medical imaging industries, guiding the organization’s growth in precision diagnostics and targeted radiopharmaceutical therapies. Continuous investment in research and development underpins Lantheus’ mission to deliver innovative solutions that improve patient outcomes and drive value for healthcare providers worldwide.

Key Stats

• Today's Range: $99.92 to $104.50
• 50-Day Range: $75.70 to $104.32
• 52-Week Range: $47.25 to $104.50
• Volume: 1.23 million shs
• Average Volume: 992,163 shs
• Market Capitalization: $6.79 billion
• P/E Ratio: 25.14
• Dividend Yield: N/A
• Price Target: $101.86
• Consensus Rating: Moderate Buy

Lantheus Stock Analysis - MarketRank™

Lantheus scored higher than 54% of companies evaluated by MarketBeat, and ranked 490th out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Lantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Lantheus is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Lantheus has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 23.01%

Earnings Growth

Earnings for Lantheus are expected to grow by 23.01% in the coming year, from $4.39 to $5.40 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lantheus is 25.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lantheus is 25.14, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.18.

Price to Book Value per Share Ratio

Lantheus has a P/B Ratio of 6.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.56% of the float of Lantheus has been sold short.

Short Interest Ratio / Days to Cover

Lantheus has a short interest ratio ("days to cover") of 4.35.

Change versus previous month

Short interest in Lantheus has recently decreased by 14.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lantheus does not currently pay a dividend.

Dividend Growth

Lantheus does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.81

News Sentiment

Lantheus has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Lantheus this week, compared to 11 articles on an average week.

Search Interest

Only 2 people have searched for LNTH on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

4 people have added Lantheus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lantheus insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of Lantheus is held by insiders.

Percentage Held by Institutions

99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/12/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LNTH
• CIK: 1521036
• Web: www.lantheus.com
• Phone: (978) 671-8001
• Fax: 978-671-8860
• Employees: 1,193
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lantheus: $101.86
• High Price Target: $115.00
• Low Price Target: $80.00
• Potential Upside/Downside: -2.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.15
• Trailing P/E Ratio: 25.14
• Forward P/E Ratio: 23.76
• P/E Growth: N/A
• Net Income: $233.56 million
• Net Margins: 18.05%
• Pretax Margin: 24.17%
• Return on Equity: 29.32%
• Return on Assets: 15.00%

Debt

• Debt-to-Equity Ratio: 0.47
• Current Ratio: 2.83
• Quick Ratio: 2.64

Sales & Book Value

• Annual Sales: $1.54 billion
• Price / Sales: 4.41
• Cash Flow: $6.64 per share
• Price / Cash Flow: 15.70
• Book Value: $16.43 per share
• Price / Book: 6.35

Miscellaneous

• Outstanding Shares: 65,110,000
• Free Float: 63,999,000
• Market Cap: $6.79 billion
• Optionable: Optionable
• Beta: -0.03